BRPI0906948A2 - Fabricação de enzinas sulfatase lisossômicas humanas ativas altamente fosforiladas e usos da mesma - Google Patents

Fabricação de enzinas sulfatase lisossômicas humanas ativas altamente fosforiladas e usos da mesma

Info

Publication number
BRPI0906948A2
BRPI0906948A2 BRPI0906948-8A BRPI0906948A BRPI0906948A2 BR PI0906948 A2 BRPI0906948 A2 BR PI0906948A2 BR PI0906948 A BRPI0906948 A BR PI0906948A BR PI0906948 A2 BRPI0906948 A2 BR PI0906948A2
Authority
BR
Brazil
Prior art keywords
manufacture
active human
lysosomal sulfatase
human lysosomal
highly phosphorylated
Prior art date
Application number
BRPI0906948-8A
Other languages
English (en)
Inventor
Michel Claude Vellard
Vish Koppaka
Melita Dvorak-Ewell
Erno Pungor
Charles Hague
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0906948(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of BRPI0906948A2 publication Critical patent/BRPI0906948A2/pt
Publication of BRPI0906948B1 publication Critical patent/BRPI0906948B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06014—N-Acetylglucosamine-6-sulfatase (3.1.6.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
BRPI0906948-8A 2008-01-18 2009-01-16 Composições compreendendo uma enzima nacetilgalactosamina-6- sulfatase (galns) recombinante humana e uso das mesmas para tratar mucopolissacaridose tipo iva, síndrome de morquio a, ou deficiência múltipla de sulfatase BRPI0906948B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US2217908P 2008-01-18 2008-01-18
US61/022.179 2008-01-18
US61/110.246 2008-01-31
US9937308P 2008-09-23 2008-09-23
US61/099.373 2008-09-23
US11024608P 2008-10-31 2008-10-31
PCT/US2009/031276 WO2009091994A2 (en) 2008-01-18 2009-01-16 Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

Publications (2)

Publication Number Publication Date
BRPI0906948A2 true BRPI0906948A2 (pt) 2015-07-14
BRPI0906948B1 BRPI0906948B1 (pt) 2023-05-16

Family

ID=40451345

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906948-8A BRPI0906948B1 (pt) 2008-01-18 2009-01-16 Composições compreendendo uma enzima nacetilgalactosamina-6- sulfatase (galns) recombinante humana e uso das mesmas para tratar mucopolissacaridose tipo iva, síndrome de morquio a, ou deficiência múltipla de sulfatase

Country Status (28)

Country Link
US (7) US8128925B2 (pt)
EP (2) EP3219795B1 (pt)
JP (1) JP5687069B2 (pt)
KR (1) KR101744142B1 (pt)
CN (2) CN102027110A (pt)
AR (1) AR070198A1 (pt)
AU (1) AU2009205978B2 (pt)
BR (1) BRPI0906948B1 (pt)
CA (2) CA2711590C (pt)
CL (1) CL2009000091A1 (pt)
CY (2) CY1118984T1 (pt)
DK (1) DK2245145T3 (pt)
HK (1) HK1244505A1 (pt)
HR (1) HRP20170366T1 (pt)
HU (2) HUE032074T2 (pt)
IL (1) IL206975A (pt)
LT (2) LT2245145T (pt)
MX (1) MX2010007846A (pt)
NL (1) NL300874I2 (pt)
NO (1) NO2017024I1 (pt)
PE (2) PE20091319A1 (pt)
PL (1) PL2245145T3 (pt)
PT (1) PT2245145T (pt)
RU (1) RU2510820C2 (pt)
SI (1) SI2245145T1 (pt)
TW (1) TWI395816B (pt)
WO (1) WO2009091994A2 (pt)
ZA (1) ZA201004674B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104480140B (zh) 2007-04-03 2019-12-31 奥克西雷恩英国有限公司 分子的糖基化
CN102027110A (zh) * 2008-01-18 2011-04-20 生物马林药物股份有限公司 制备活性高度磷酸化人溶酶体硫酸酯酶及其应用
CN104651428A (zh) 2009-09-29 2015-05-27 根特大学 水解甘露糖-1-磷酸-6-甘露糖连接为磷酸-6-甘露糖
BR112012011980A2 (pt) 2009-11-19 2021-09-08 Oxyrane Uk Limited Métodos de produzir células transformadas de yarrowia lipolytica e proteínas-alvocompreendendo n-glicanos, células transformadas de yarrowia lipolytica e suas culturas, bem como composição compreendendo glicoproteínas
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
US9689015B2 (en) 2010-09-29 2017-06-27 Oxyrane Uk Limited De-mannosylation of phosphorylated N-glycans
CN103328646B (zh) 2010-09-29 2021-06-18 奥克西雷恩英国有限公司 能够使甘露糖-1-磷酸-6-甘露糖连接脱帽并使磷酸化的n-聚糖脱甘露糖基化的甘露糖苷酶及促进糖蛋白的哺乳动物细胞摄取的方法
WO2012063984A1 (ko) * 2010-11-12 2012-05-18 주식회사 녹십자 개량형 이듀로네이트-2-설파타제 및 이의 용도
AU2010366066B2 (en) * 2010-12-22 2016-01-14 Fondazione Telethon Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses
TW201307563A (zh) 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素－ｎ－硫酸酯酶之方法
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US9249399B2 (en) 2012-03-15 2016-02-02 Oxyrane Uk Limited Methods and materials for treatment of pompe's disease
WO2013148323A1 (en) * 2012-03-30 2013-10-03 Shire Human Genetic Therapies Methods of analyzing and preparing protein compositions
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
WO2014075688A1 (en) * 2012-11-13 2014-05-22 Ace Biosciences A/S PURIFICATION OF RECOMBINANT HUMAN GALACTOCEREBROSIDE β-GALACTOSIDASE (rhGALC)
WO2014136065A2 (en) * 2013-03-05 2014-09-12 Oxyrane Uk Limited Production of catalytically active type i sulfatase
JP6684715B2 (ja) * 2014-02-18 2020-04-22 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド リソソーム酵素のための基質クリアランスアッセイ
PT2970413T (pt) * 2014-04-01 2018-10-23 Swedish Orphan Biovitrum Ab Publ Sulfamidase modificada e sua produção
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
MX2018005258A (es) 2015-11-06 2019-09-04 Biomarin Pharm Inc Ensayos basados en células para la detección de anticuerpos u otros factores que neutralizan la absorción de enzimas lisosómicas.
RU2673038C2 (ru) * 2016-01-18 2018-11-21 ООО "Международный Биотехнологический Центр "Генериум" Лекарственное средство на основе бифункционального антитела для лечения мукополисахаридоза II типа
JP6430980B2 (ja) * 2016-03-09 2018-11-28 フォンダッツィオーネ・テレソン ムコ多糖症におけるｃｎｓ病変を処置するための治療戦略
WO2019045149A1 (en) 2017-08-31 2019-03-07 Green Cross Corporation PROCESS FOR PURIFYING SULFATASE PROTEIN
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
EP3963073A4 (en) * 2019-04-29 2023-01-25 The University of North Carolina at Chapel Hill OPTIMIZED SUMF1 GENES AND EXPRESSION CASSETTE AND THEIR USE
RU2763990C2 (ru) * 2020-02-19 2022-01-12 Акционерное общество "ГЕНЕРИУМ" Клетка, продуцирующая с высокой эффективностью активный белок арилсульфатазу в, и способ получения этой клетки
MX2023004335A (es) 2020-10-14 2023-05-04 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas.
KR20240045299A (ko) * 2021-08-18 2024-04-05 조인트-스톡 컴퍼니 "제네리움" 치료 효소의 표적화 전달

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US6972124B2 (en) 2000-05-01 2005-12-06 Biomarin Pharmaceuticals Inc. Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
EP1395669B1 (en) 2001-01-26 2009-07-22 Selexis S.A. Matrix attachment regions and methods for use thereof
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
AUPS293002A0 (en) 2002-06-14 2002-07-04 Women's And Children's Hospital Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders
ES2566641T3 (es) * 2003-02-11 2016-04-14 Shire Human Genetic Therapies, Inc. Células que co-expresan una enzima que genera a una sulfatasa y una C-formiliglicina y sus métodos y usos
CA2554883C (en) * 2004-01-30 2013-10-01 Zymenex A/S Production and purification of recombinant arylsulfatase a
WO2005077093A2 (en) 2004-02-06 2005-08-25 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
WO2005113765A2 (en) * 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
CA2607133A1 (en) 2005-05-02 2006-11-09 Toray Industries, Inc. Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer
EP1818395A1 (en) 2006-02-08 2007-08-15 Diatos Compositions and methods for treating lysosomal storage diseases
AU2008205410B2 (en) * 2007-01-05 2013-10-10 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
WO2009034159A1 (en) 2007-09-12 2009-03-19 Vivendy Therapeutics Ltd: Short polypeptide mediated conformational changes promoting enhancement of enzymatic activity
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
CN102027110A (zh) * 2008-01-18 2011-04-20 生物马林药物股份有限公司 制备活性高度磷酸化人溶酶体硫酸酯酶及其应用
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos

Also Published As

Publication number Publication date
CA3112632A1 (en) 2009-07-23
CL2009000091A1 (es) 2009-03-27
DK2245145T3 (en) 2017-03-20
IL206975A (en) 2013-06-27
LTPA2017016I1 (lt) 2017-06-12
EP3219795A1 (en) 2017-09-20
PE20091319A1 (es) 2009-09-23
PT2245145T (pt) 2017-03-14
US20180208913A1 (en) 2018-07-26
PE20140841A1 (es) 2014-08-03
WO2009091994A2 (en) 2009-07-23
US8128925B2 (en) 2012-03-06
JP5687069B2 (ja) 2015-03-18
RU2510820C2 (ru) 2014-04-10
IL206975A0 (en) 2010-12-30
AR070198A1 (es) 2010-03-17
CY1118984T1 (el) 2017-11-14
US20090186011A1 (en) 2009-07-23
TWI395816B (zh) 2013-05-11
WO2009091994A3 (en) 2009-10-29
ZA201004674B (en) 2011-09-28
MX2010007846A (es) 2010-10-05
US9200264B2 (en) 2015-12-01
PL2245145T3 (pl) 2017-07-31
CA2711590C (en) 2021-03-23
WO2009091994A9 (en) 2009-12-03
BRPI0906948B1 (pt) 2023-05-16
US20200181590A1 (en) 2020-06-11
LTC2245145I2 (lt) 2019-04-25
LT2245145T (lt) 2017-04-10
US10934534B2 (en) 2021-03-02
KR101744142B1 (ko) 2017-06-07
US9873867B2 (en) 2018-01-23
US8420368B2 (en) 2013-04-16
CA2711590A1 (en) 2009-07-23
US20120208221A1 (en) 2012-08-16
AU2009205978A1 (en) 2009-07-23
KR20100108438A (ko) 2010-10-06
US20130236921A1 (en) 2013-09-12
HRP20170366T1 (hr) 2017-05-05
CN105274072A (zh) 2016-01-27
EP2245145B1 (en) 2016-12-14
SI2245145T1 (sl) 2017-05-31
NL300874I2 (nl) 2018-04-12
HUS1700022I1 (hu) 2017-06-28
US10563183B2 (en) 2020-02-18
CY2017018I2 (el) 2017-11-14
TW200934869A (en) 2009-08-16
CY2017018I1 (el) 2017-11-14
JP2011509674A (ja) 2011-03-31
HUE032074T2 (en) 2017-08-28
AU2009205978B2 (en) 2014-04-10
EP2245145A2 (en) 2010-11-03
RU2010134412A (ru) 2012-02-27
US20160201039A1 (en) 2016-07-14
NO2017024I1 (no) 2017-05-30
CN102027110A (zh) 2011-04-20
US20210189357A1 (en) 2021-06-24
HK1244505A1 (zh) 2018-08-10
EP3219795B1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
BRPI0906948A2 (pt) Fabricação de enzinas sulfatase lisossômicas humanas ativas altamente fosforiladas e usos da mesma
BRPI0810480A2 (pt) Variantes da enzima asparaginase e usos das mesmas
IL260282B (en) Human acetylgalactosamine-6-sulfatase-n production of highly active phosphorylated and its uses
BRPI0908143A2 (pt) Agente de branqueamento e preparação externa da pele
BRPI0917378A2 (pt) tratamento da transpiracao e da hiperidrose
BRPI0919519A2 (pt) Composição, agente herbicida, e, usos de herbicida, e da composição
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
BRPI1011830A2 (pt) microencapsulação de substância bioativas e métodos de preparação da mesma
BRPI0909037A2 (pt) compostos e composições como moduladores da atividade de tlr
BRPI0810481A2 (pt) Novas asparaginases e usos destas
BRPI0912225A2 (pt) peptídeos de direcionamento lisossomais e usos dos mesmos
EP2155197A4 (en) TREATMENT OF LYSOSOMAL STORAGE DISEASES
BRPI0922180A2 (pt) insoindolinona e análogos correlatos como moduladores de sirtuína
EP2480669A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH FILAGRIN (FLG) BY MODULATION OF FLG EXPRESSION AND ACTIVITY
BRPI0716466A2 (pt) Tratamento da calda de açúcar
EP2240187A4 (en) INGREDIENTABLE ABSORBENT AGENTS AND METHODS OF MAKING AND USING SAME
BRPI0907750A2 (pt) Variantes de alfa-amilase de bacillus stearothermophilus e usos dos mesmos
DK2977057T3 (da) Isoleret rekombinant human N-glycosyleret lysosomal syrelipase
BRPI1010517A2 (pt) métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal
EP2063902A4 (en) THERAPEUTIC CELL MEDICAMENT WITH STEM CELLS OF SKIN
BRPI0822143A2 (pt) derivados de dicicloaza-alcano, processos de preparação e usos médicos dos mesmos
BRPI0915482A2 (pt) derivados de 2-oxo-alquil-1-piperazin-2-ona, seus processos de preparação e usos, e composições farmacêuticas e medicamentos compreendendo os mesmos
BR112012003026A2 (pt) formulações e métodos de emprego de desinfetante anidro.
EP2408907B8 (en) Use of cellulose and ligno-cellulose active proteins
WO2012084424A3 (de) Wirkstoffkombinationen aus glucosylglyceriden und einem oder mehreren kationischen polymeren

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/01/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.